Shire U.S., Inc. v. Johnson Matthey, Inc.

543 F. Supp. 2d 404, 2008 U.S. Dist. LEXIS 11000, 2008 WL 399333
CourtDistrict Court, E.D. Pennsylvania
DecidedFebruary 14, 2008
DocketCivil 07-CV-2958
StatusPublished
Cited by17 cases

This text of 543 F. Supp. 2d 404 (Shire U.S., Inc. v. Johnson Matthey, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Shire U.S., Inc. v. Johnson Matthey, Inc., 543 F. Supp. 2d 404, 2008 U.S. Dist. LEXIS 11000, 2008 WL 399333 (E.D. Pa. 2008).

Opinion

MEMORANDUM & ORDER

RUFE, District Judge.

This is a declaratory judgment action involving a question of patent infringe *406 ment. Presently before the Court is Defendants’ Motion to Dismiss, or in the Alternative, to Transfer or Stay, the action. 1 For the following reasons, the Motion to Dismiss will be granted.

BACKGROUND

Plaintiffs Shire U.S., Inc. and Shire Pharmaceuticals Ireland Limited (collectively, “Shire”) seek a judgment that they do not infringe a patent assigned to Defendants Johnson Matthey, Inc., and/or Johnson Matthey PLC (Defendants collectively, “Johnson Matthey”). 2 Both Plaintiffs and Defendants have their United States corporate headquarters in Wayne, Pennsylvania. The patent at issue, U.S. Patent No. 6,096,760, entitled “Solid a-phenyl-2-piperidine Acetate Free Base, Its Preparation and Use in Medicine,” claims methylphenidate base and methods for its production and use (“the '760 patent”). Methylphenidate is a compound which can be used in the treatment of attention-deficit hyperactivity disorder (ADHD). The base form of methylpheni-date is applied to transdermal patches often used to treat children with ADHD. The '760 patent issued on August 1, 2000, to inventor Chester Sapino, and was assigned sometime thereafter to Johnson Matthey.

Shire is the exclusive licensee and global distributor of a product marketed under the trademark Daytrana. Daytrana is a pharmaceutical patch that delivers methyl-phenidate base transdermally. It is manufactured by Noven Pharmaceuticals, Inc. (“Noven”), a Delaware corporation with its principal place of business in Miami, Florida. 3

On June 19, 2007, Johnson Matthey filed a complaint against Noven in the U.S. District Court for the Eastern District of Texas, claiming that Noven infringed the '760 patent by manufacturing Daytrana (“the Texas Action”). 4 Shire was not named as a defendant in the Texas Action at the time. Approximately one month later, on July 18, 2007, Shire instituted this action for declaratory judgment, seeking a ruling that it does not infringe the '760 patent by distributing Daytrana. Subsequently, on July 23, 2007, Johnson Mat-they amended the complaint in the Texas Action to include Shire as a defendant on the basis of Shire’s alleged infringement of the '760 patent through its distribution of Daytrana. 5

Johnson Matthey moved to dismiss, or in the alternative, to transfer or stay this action on August 15, 2007. After reviewing the Motion, the response thereto, and the reply and sur-reply thereto, and hearing oral argument on the same, this matter is now ready for decision.

DISCUSSION

Johnson Matthey argues this Court *407 should exercise its discretion 6 to dismiss Shire’s declaratory judgment action on the basis of the “fírst-to-fíle” rule, the doctrine of federal comity applicable to venue or forum disputes involving similar, concurrent actions in different jurisdictions. Under the rule, the forum of the first-filed case is favored unless fairness or efficiency considerations require otherwise. 7 Defendants contend that the rule compels this Court to yield to the Texas Action because the Texas Action was earlier-filed, and involves identical factual and legal questions to those involved here — namely, whether Daytrana infringes the '760 patent. Johnson Matthey asserts that it is immaterial to the first-to-file analysis that Shire was not made a party to the Texas Action until after the instant action was filed because the rule “turns on which court first obtains possession of the subject of the dispute, not the parties of the dispute.” 8 Defendants further argue that no efficiency or justice considerations appear that would justify something other than the ordinary application of the first-to-file rule in this case. Finally, Defendants forward several alternative arguments, should the Court reject their primary argument on the application of the first-to-file rule. 9

Shire agrees that the first-to-file rule should govern the disposition of this matter, but contends that the rule here favors the Pennsylvania forum. 10 Shire’s position apparently is based on a view that the identity of the parties in the disputes is central to the first-to-file inquiry. Thus, Plaintiffs assert the instant action was first-filed, relative to the Texas Action, because this action was the first to involve Shire as a party. Further focusing on the identity of parties, Shire rejects the proposition that the amended complaint adding it as a defendant in the Texas Action “relates back” to the original date of filing under Federal Rule of Civil Procedure 15(c)(3), arguing that Defendants cannot make out the conditions necessary to support relation back under that Rule. Moreover, Shire claims that Johnson Matthey cannot benefit from the first-to-file rule in any event because its filing in Texas and failure to sue Shire there in the first instance constitute bad faith litigation conduct which renders the rule inapplicable. Plaintiffs also address Defendants’ alternative request for transfer, arguing that the relevant public and private interests under 28 U.S.C. § 1404(a) weigh decidedly against transfer in this case.

Federal district courts have jurisdiction to adjudicate declaratory judgment actions pursuant to the Declaratory Judgment Act. 11 Jurisdiction under the Act is discretionary. 12 As such, a district court may decline to hear a declaratory judg *408 ment action for a “sound reason.” 13 A district court abuses its discretion to dismiss a declaratory judgment action where it does so on the basis of incorrect legal conclusions, erroneous findings of fact, inadequate supporting evidence, or in an otherwise arbitrary or unreasonable manner. 14 In general, the decision whether or not to adjudicate a declaratory judgment action is properly informed by “considerations of practicality and wise judicial administration.” 15

District courts apply substantive patent law as articulated by the Court of Appeals for the Federal Circuit, as well as Federal Circuit rulings on matters of procedural law which affect “national uniformity in patent practice.” 16

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
543 F. Supp. 2d 404, 2008 U.S. Dist. LEXIS 11000, 2008 WL 399333, Counsel Stack Legal Research, https://law.counselstack.com/opinion/shire-us-inc-v-johnson-matthey-inc-paed-2008.